Table 4.

Association between statin use and estrogen receptor positive (ER+) and negative (ER−) tumors

Statin use	ER+ cases		ER− cases
		Multivariable-adjusted HR (95% CI)*		Multivariable-adjusted HR (95% CI)*
All women	n=2,067 %		n=373 %
Never	95.1	Referent	94.4	referent
Ever	4.9	1.06 (0.85–1.32)	5.6	1.28 (0.78–2.08)
Current	4.7	1.10 (0.88–1.37)	4.8	1.16 (0.69–1.95)
Duration of use among women with 5+ years of data**	n=1,315 %		n=218 %
Never	93.6	referent	90.7	referent
1–2.9 yrs	2.6	0.93 (0.66–1.32)	3.7	1.33 (0.64–2.77)
3–4.9 yrs	1.7	0.98 (0.63–1.51)	2.8	1.68 (0.72–3.92)
5+ yrs	2.1	1.24 (0.83–1.86)	2.8	1.81 (0.75–4.36)

HR=hazard ratio and CI=confidence interval

^*Multivariable-adjusted models include age, HT use, diabetes, other lipid lowering drug use, and BMI.

^**p=0.5 from linear trend test for the effect of the duration of statin use on risk of ER+ tumor

p=0.08 from linear trend test for the effect of the duration of statin use on risk of ER− tumor